Pulmonary arterial hypertension in patients treated by dasatinib

May 17, 2012

Overview:Background Chronic myelogenous leukemia (CML) is a chronic myeloproliferative disorder. The prognosis of CML has been transformed by tyrosine kinase inhibitors (TKIs), such as dasatinib. Knowledge Gap Although TKIs are usually well tolerated, these agents are nonetheless characterized by systemic toxicity... more

Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation MI patients with expected delays due to long-distance transfers

Jun 18, 2012

Overview:This investigates the safety and efficacy of a pharmaco-invasive reperfusion strategy utilizing half-dose fibrinolysis combined with transfer for immediate PCI in STEMI patients presenting to remote rural hospitals. The authors found no significant differences in 30-day mortality, stroke, major bleeding,... more

Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis

Oct 12, 2014

Overview:  Background and knowledge gap According to current guidelines, a rhythm-control strategy (including pharmacological or electrical cardioversion) in patients with chronic HF, has not been demonstrated to be superior to a rate-control strategy in reducing mortality or morbidity. Preference of... more

Retraction of the Jikei Heart Study

Oct 21, 2013

Overview:In 2007, the Lancet published the results of the Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study (1). According to the authors, the addition of the angiotensin... more

Resistant Hypertension: A Real Entity Requiring Special Treatment?

Resistant Hypertension: A Real Entity Requiring Special Treatment?

Aug 01, 2016

Overview:The concept of resistant hypertension (RH) has received great attention in the past years, mainly as a possible target population for innovative therapeutic strategies. An increasing number of original articles and commentaries have focused on the clinical significance, prognosis and... more

Typical angina without significant coronary stenosis: comparison of clinical profile, circadian presentation, and long-term follow-up between patients with and patients without vasospastic angina

Aug 07, 2013

Overview:Background The spectrum of patients with chest and no significant coronary stenosis is broad, with a wide range of lumen obstruction (from smooth completely normal coronary arteries to those with lesions <50%) and also including abnormal vasomotion (vasospastic angina-VA, microvascular... more

Left Ventricular Remodelling: A Problem In Search Of Solutions

Left Ventricular Remodelling: A Problem In Search Of Solutions

Mar 01, 2018

Overview:  The term cardiac remodelling (REM) is used to define changes that produce geometrical rearrangement of the normal structures of the heart, together with complex biological and molecular alterations. REM affects the heart at the level of the cardiomyocyte, the... more

High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study

Jun 18, 2012

Overview:The authors of this study investigated whether there is a difference between younger and older patients in the ability of thienopyridine antiplatelet drugs to inhibit platelet responsiveness. They found that, in a population of patients chronically treated with aspirin plus... more

Ranolazine reduces patient-reported angina severity and frequency and improves quality of life in selected patients with chronic angina

Feb 20, 2014

Overview:Background and objectives: Coronary heart disease (CHD) is the most common cause of death (and premature death) in the United Kingdom (UK) with 94,000 deaths from CHD in the UK each year (1 in 5 men and 1 in 7... more

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomization study

Jun 18, 2012

Overview:The present study sought to assess whether there is a causal relationship between raising HDL and the risk for myocardial infarction (MI). Using a mendelian randomization, the authors found that in patients with genetically higher HDL the risk of MI... more

Page: